Pharmaceutical Nanotechnology publishes original manuscripts, full-length/mini reviews, thematic issues, rapid technical notes and commentaries that provide insights into the synthesis, characterisation and pharmaceutical (or diagnostic) application of materials at the nanoscale. The nanoscale is defined as a size range of below 1 µm. Scientific findings related to micro and macro systems with functionality residing within features defined at the nanoscale are also within the scope of the journal. Manuscripts detailing the synthesis, exhaustive characterisation, biological evaluation, clinical testing and/ or toxicological assessment of nanomaterials are of particular interest to the journal’s readership. Articles should be self contained, centred around a well founded hypothesis and should aim to showcase the pharmaceutical/ diagnostic implications of the nanotechnology approach. Manuscripts should aim, wherever possible, to demonstrate the in vivo impact of any nanotechnological intervention. As reducing a material to the nanoscale is capable of fundamentally altering the material’s properties, the journal’s readership is particularly interested in new characterisation techniques and the advanced properties that originate from this size reduction. Both bottom up and top down approaches to the realisation of nanomaterials lie within the scope of the journal.
Ijeoma F. Uchegbu Department of Pharmaceutics University of London London UK
Ijeoma Uchegbu is Professor of Pharmaceutical Nanoscience at the UCL School of Pharmacy, University College London (UCL), Pro-Vice Provost for Africa and The Middle East, UCL and Chief Scientific Officer of Nanomerics. She obtained her PhD from the School of Pharmacy, University of London in 1994. In 2015, Ijeoma became UCL’s Pro-Vice Provost for Africa and The Middle East. Nanomerics was founded in 2010 by Ijeoma and Andreas G. Schätzlein. Nanomerics is a specialtiy pharmaceutical company focused on exploiting pharmaceutical nanotechnology platforms for medicines development. Ijeoma has been awarded various prizes for her work, notably the UK Department for Business Innovation Skills’ Women of Outstanding Achievement in Science Engineering and Technology award and the Royal Pharmaceutical Society’s Pharmaceutical Scientist of the Year 2012. Ijeoma was elected to the Controlled Release Society College of Fellows in 2013 and became an Eminent Fellow of the Academy of Pharmaceutical Sciences in 2013.